Summary
The purpose of this clinical trial is to learn the safety and effects of a new drug (called PF-07799544) when administered alone and in combination with other medication in people with solid cancers.
The study has two parts. In Phase 1a where PF-07799544 was given by itself. Phase 1a is not longer open to recruitment.
In Phase 1b, PF-07799544 will be given with another study medicine (called PF-07799933).
In Phase 1b (described below), researchers are seeking participants who have:
- a solid tumour which is metastatic or recurrent (excluding colorectal cancer)
- tumour with a mutation n(abnormal gene) called "BRAF V600"
- received required prior treatment for cancer per cohort assigned.
All participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day.
Participants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective.